CompletedPhase 2NCT01807546
Oral Rigosertib for Squamous Cell Carcinoma
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Traws Pharma, Inc.
- Principal Investigator
- Michael Kurman, MDTraws Pharma, Inc.
- Intervention
- rigosertib(drug)
- Enrollment
- 64 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2016
Study locations (13)
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Stanford Cancer Institute, Stanford, California, United States
- University of Colorado School of Medicine, Aurora, Colorado, United States
- Denver VA Medical Center-ECHCS, Denver, Colorado, United States
- University of Michigan Health System, Ann Arbor, Michigan, United States
- Veterans Administration New Jersey Health Care System, East Orange, New Jersey, United States
- Mount Sinai Medical Center, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Ohio State University, James Cancer Hospital, Columbus, Ohio, United States
- University of Pennslvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
- Mary Crowley Cancer Research Center, Dallas, Texas, United States
- Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
- Blue Ridge Cancer Care, Salem, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01807546 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →